Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Foresite Capital Management V, LLC

Q2 2023 · 13F-HR

Foresite Capital Management V, LLCholdings as filed

Filed 2023-08-11 · accession 0001104659-23-090058

$136.9M
Reported value
10
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
433000106HIMSHims & Hers Health, Inc.$35.1M25.6%3,733,381CommonSOLE
88369M101Theseus Pharmaceuticals, Inc.$33.5M24.4%3,585,346CommonSOLE
69945Q105Pardes Biosciences Inc$19.6M14.3%10,811,887CommonSOLE
00461U105ACRSAclaris Therapeutics, Inc.$13.0M9.53%1,258,243CommonSOLE
254604101IRONDisc Medicine, Inc.$10.8M7.90%243,513CommonSOLE
49705R105KNTEUSDKinnate Biopharma Inc.$10.7M7.80%3,525,957CommonSOLE
83444K105SLGCUSDSomalogic, Inc.$7.9M5.74%3,403,276CommonSOLE
20454B104CMPXCompass Therapeutics, Inc.$4.2M3.08%1,324,071CommonSOLE
74765K105QSIQuantum Si Inc$1.7M1.21%924,404CommonSOLE
N69605108PHVSPharvaris N.V.$516,9100.38%34,142CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.